jamie_gault__novella

New leadership roles at Novella Clinical

pharmafile | September 5, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing CRO, novella clinical 

Contract research organisation Novella Clinical has announced that three senior executives have assumed new leadership roles within the firm.

Deborah Turunjian has been named vice president, Oncology Clinical Development and will lead the expansion of Novella’s oncology division. Previously, Turunjian served as executive leadership for the firm’s business optimisation and vendor management departments in addition to her oversight of western US business operations.

Jamie Gault (pictured) has been promoted to global head of Regulatory Affairs and will oversee preparation of regulatory packages for agencies globally. Having joined Novella in 2012 in a senior quality assurance role, Gault has 25 years experience in regulatory roles both at sponsor and CRO organisations.

Finally Kathleen Zajd has been named vice president, Global Quality & Compliance. She became an integral part of the Novella senior management team as a result of its acquisition of Prologue Research International in 2010. 

Novella Clinical’s president and chief executive Richard Staub, said: “We are fortunate to work with an extremely high caliber of professionals. I am confident we have the right people in the right positions to propel Novella into our next phase of growth.”

Related Content

Science image

Drug development contracts: can lessons be learned from healthcare delivery?

There is a very good question to ask at the beginning of every project: “What …

Covance image

LabCorp buys Covance for $6.1 billion

US medical diagnostics firm LabCorp has entered the drug development business via a $6.1 billion …

Parexel acquires ClinIntel for trial supply services

Clinical research organisation Parexel has acquired all of the outstanding equity securities of privately-owned ClinIntel, …

Latest content